C. Kahl

B. Storer, M. Mielcarek, B. Torok-Storb, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

D. Niederwieser, S. Scholl, C. Junghanss, 2021, Annals of Hematology.

Myeloid/natural killer cell precursor blast crisis of chronic myelogenous leukemia with two Philadelphia (Ph-1) chromosomes

A. Franke, A. Pelz, K. Jentsch‐Ullrich, 2001, Annals of Hematology.

Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).

W. Scheithauer, V. Heinemann, J. Holch, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia

H. Döhner, M. Stauch, M. Hallek, 2012, Leukemia.

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)

D. Niederwieser, S. Scholl, C. Junghanss, 2015, Journal of Cancer Research and Clinical Oncology.

Nonmyeloablative and Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies: Outcomes with HLA-Matched Unrelated Donors Compared to HLA-Identical Sibling Donors.

M. Maris, R. Storb, B. Sandmaier, 2005 .

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

W. Hiddemann, B. Dörken, A. Krämer, 2023, Annals of Hematology.

Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)

D. Niederwieser, M. Cross, H. Al-Ali, 2017 .

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

W. Hiddemann, A. Krämer, D. Niederwieser, 2016 .

Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma—a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO)

M. Herold, M. Assmann, H. Eschenburg, 2004, Leukemia & lymphoma.

Bendamustine, Methotrexate, Mitoxantrone, and Prednisolone (BMMP) for the Treatment of Relapsed or Refractory High-Grade Non-Hodgkin’s Lymphoma

M. Herold, A. Franke, C. Kahl, 1997 .

Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial

A. Ganser, G. Behre, A. Hinke, 2014, Bone Marrow Transplantation.

Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stem cell transplantation

A. Hinke, M. Freund, H. Sayer, 2012, Journal of Cancer Research and Clinical Oncology.

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

W. Scheithauer, M. Stauch, V. Heinemann, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study

T. Fischer, E. Schalk, C. Kahl, 2019, Annals of Hematology.

First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis

W. Klapper, A. Stroux, M. Herold, 2020, Annals of Hematology.

Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259].

W. Scheithauer, V. Heinemann, T. Decker, 2022, European journal of cancer.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

W. Scheithauer, M. Stauch, V. Heinemann, 2017, European journal of cancer.

Relevance of liver‐limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE‐3/AIO KRK0306 trial

W. Scheithauer, V. Heinemann, J. Holch, 2018, International journal of cancer.

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

Michael Scholz, Volker Heinemann, W. Scheithauer, 2013 .

Association of microRNA-21 with efficacy of cetuximab in RAS wild-type patients in the FIRE-3 study (AIO KRK-0306) and microRNA-21’s influence on gene expression in the EGFR signaling pathway.

W. Scheithauer, V. Heinemann, S. Al-Batran, 2019, Journal of Clinical Oncology.

Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).

W. Scheithauer, V. Heinemann, T. Decker, 2018 .

Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

W. Scheithauer, M. Stauch, V. Heinemann, 2015 .

Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.

W. Scheithauer, V. Heinemann, T. Decker, 2018 .

Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.

M. Maris, R. Storb, B. Sandmaier, 2005 .

Primary Intracranial Manifestation of CD7/CD56-Positive Acute Myelogenous Leukemia

K. Dietzmann, A. Franke, C. Kahl, 2000, Oncology Research and Treatment.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

A. Kiani, S. Al-Batran, T. Kirchner, 2017, European journal of cancer.

FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study

V. Heinemann, G. Prager, J. Taieb, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

W. Scheithauer, V. Heinemann, J. Holch, 2019, European journal of cancer.

Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306).

W. Scheithauer, M. Stauch, V. Heinemann, 2017 .

Inflammation Induced Expression of Ybx1 Mediates Resistance to JAK-Kinase Inhibitor Therapy in Myeloproliferative Neoplasia

F. Heidel, T. Fischer, P. Mertens, 2014 .

Invasive zygomycosis in patients with graft‐versus‐host disease after allogeneic stem cell transplantation

C. Junghanss, F. Prall, M. Freund, 2009, Transplant infectious disease : an official journal of the Transplantation Society.